Sertraline

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Impulse Control Disorders

Conditions

Impulse Control Disorders

Trial Timeline

Jan 1, 2000 → Aug 1, 2004

NCT ID

NCT00118014

About Sertraline

Sertraline is a approved stage product being developed by Pfizer for Impulse Control Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00118014. Target conditions include Impulse Control Disorders.

What happened to similar drugs?

1 of 1 similar drugs in Impulse Control Disorders were approved

Approved (1) Terminated (0) Active (0)

✅Levodopa/Carbidopa(200mg/50mg) + Dopaminergic AgonistsSandoz GroupApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01302080	Pre-clinical	Completed	Apr 4, 2012	Sep 9, 2020	Obsessive Compulsive Disorder
NCT00585455	Pre-clinical	Terminated	Jan 1, 2006	Jul 1, 2009	Heart Failure
NCT00245557	Pre-clinical	Completed	Nov 1, 2004	Aug 1, 2008	Major Depressive Disorder
NCT02122393	Phase 3	Completed	Apr 1, 2002	Apr 1, 2005	Depression
NCT00118014	Approved	Completed	Jan 1, 2000	Aug 1, 2004	Impulse Control Disorders

Competing Products

1 competing product in Impulse Control Disorders

See all competitors

Product	Company	Stage	Hype Score
Levodopa/Carbidopa(200mg/50mg) + Dopaminergic Agonists	Sandoz Group	Approved	40